Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Hill et al., Research Square, doi:10.21203/rs.3.rs-148845/v1

Jan 2021

Source PDF All Studies Meta AnalysisMeta

Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose and duration dependent), improved clinical recovery, and lower hospitalization and mortality. In six RCTs of moderate or severe infection, there was a 75% reduction in mortality, RR 0.25 [0.12-0.52], p = 0.0002.

A documentary about the external influences changing the conclusions of this study, and the resulting negative impacts, can be found at drtesslawrie.substack.com.

A sponsor reportedly required the conclusion of this paper to be changed against the wishes of the authors (to suggest that more trials should be done as opposed to the existing evidence being sufficient) francesoir.fr, reddit.com, youtube.com. Reportedly, Unitaid had influence over the conclusions trialsitenews.com, worldcouncilforhealth.org. See also roundingtheearth.substack.com.

Note that one of the 18 studies in this analysis has since been withdrawn (Elgazzar).

7 meta analyses show significant improvements with ivermectin for mortality Bryant, Hariyanto, Kory, Lawrie, Nardelli, Zein, hospitalization Schwartz, recovery Kory, and cases Kory.

Currently there are 99 ivermectin for COVID-19 studies, showing 49% lower mortality [35‑60%], 29% lower ventilation [13‑42%], 38% lower ICU admission [14‑56%], 34% lower hospitalization [20‑45%], and 81% fewer cases [71‑87%].

1. Bryant et al., Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001402.lww.com, doi.org.

2. drtesslawrie.substack.com, drtesslawrie.substack.com/p/a-letter-to-dr-andrew-hill.drtesslawrie.substack.com/p/a-letter-to-dr-andrew-hill.

3. francesoir.fr, www.francesoir.fr/videos-les-debriefings/le-scandale-de-livermectine-tess-lawrie-le-retour.www.francesoir.fr/videos-les-debriefings/le-scandale-de-livermectine-tess-lawrie-le-retour.

4. Hariyanto et al., Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies, Reviews In Medical Virology, doi:10.1002/rmv.2265.wiley.com, doi.org.

5. Kory et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377.lww.com, doi.org.

6. Lawrie et al., Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance, Preprint, b3d2650e-e929-4448-a527-4eeb59304c7f.filesusr.com/ugd/593c4f_8cb655bd21b1448ba6cf1f4c59f0d73d.pdf.filesusr.com.

7. Nardelli et al., Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?, Signa Vitae, doi:10.22514/sv.2021.043.signavitae.com, doi.org.

8. reddit.com, www.reddit.com/r/ivermectin/comments/m5kr7b/dr_tess_lawrie_discusses_her_ivermectin/.www.reddit.com/r/ivermectin/comments/m5kr7b/dr_tess_lawrie_discusses_her_ivermectin/.

9. roundingtheearth.substack.com, roundingtheearth.substack.com/p/who-manages-unitaid-context-behind.roundingtheearth.substack.com/p/who-manages-unitaid-context-behind.

10. Schwartz, E., Does ivermectin have a place in the treatment of mild Covid-19?, New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989.sciencedirect.com, doi.org.

11. trialsitenews.com, trialsitenews.com/the-case-of-dr-andrew-hill-was-their-unethical-activity-associated-with-his-ivermectin-meta-analysis-or-just-another-drug-dev-day/.trialsitenews.com/the-case-of-dr-andrew-hill-was-their-unethical-activity-associated-with-his-ivermectin-meta-analysis-or-just-another-drug-dev-day/.

12. worldcouncilforhealth.org, worldcouncilforhealth.org/multimedia/tess-lawrie-conversation-andrew-hill/.worldcouncilforhealth.org/multimedia/tess-lawrie-conversation-andrew-hill/.

13. youtube.com, www.youtube.com/watch?v=y2FWPQm6sxw&t=3s.www.youtube.com/watch?v=y2FWPQm6sxw&t=3s.

14. Zein et al., Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.102186.sciencedirect.com, doi.org.

Important missing comments or errors? Let us know.

risk of death, 75.0% lower, RR 0.25, p < 0.001.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Hill et al., 19 Jan 2021, preprint, 40 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Dr Andrew Hill, Ahmed S Abdulamir, Sabeena Ahmed, Asma Asghar, Olufemi Emmanuel Babalola, Rabia Basri, Carlos Chaccour, Aijaz Zeeshan Khan Chachar, Abu Tauib Mohammed Chowdhury, Ahmed Elgazzar, Leah Ellis, Jonathan Falconer, Anna Garratt, Basma M Hany, Hashim A Hashim, Wasim Ul Haque, Arshad Hayat, Shuixiang He, Ramin Jamshidian, Wasif Ali Khan, Ravi Kirti, Alejandro Krolewiecki, Carlos Lanusse, Jacob Levi, Reaz Mahmud, Sermand Ahmed Mangat, Kaitlyn Mccann, Anant Mohan, Mortezza Shakshi Niaee, Nurullah Okumus, Victoria Pilkington, Chinmay Saha Podder, Ambar Qavi, Houssam Raad, Mohammaed Sadegh Rezai, Surapaneni Sasank, Veerapaneni Spoorthi, Tejas Suri, Junzheng Wang, Hannah Wentzel

doi:10.21203/rs.3.rs-148845/v1

Forum Infectious Diseases published a version of this preprint. The authors subsequently learned that one of the studies on which this analysis was based had been withdrawn due to fraudulent data. An expression of concern was issued on August 9, 2021.

References

Ahmed, Karim, Ross, Hossain, Clemens et al., A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.191

Arshad, Pertinez, Box, Tatham, Rajoli et al., Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clin Pharmacol Ther, doi:10.1002/cpt.1909

Asghar, Efficacy of Ivermectin in COVID-19

Babaloa, Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos, doi:10.1186/ISRCTN40302986

Babalola, None, medRxiv, doi:10.1101/2021.01.05.21249131

Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787

Canga, Prieto, Liébana, Martínez, Vega et al., The pharmacokinetics and interactions of ivermectin in humans--a mini-review, AAPS J, doi:10.1208/s12248-007-9000-9

Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral

Chachar, Khan, Asif, Khaqan, Basri, Effectiveness of ivermectin in SARS-CoV-2 / COVID-19 patients, International Journal of Sciences, doi:10.18483/ijSci.2378

Chowdhury, A randomised trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients, doi:10.21203/rs.3.rs-38896/v1

Ci, Li, Yu, Zhang, Yu et al., Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol, doi:10.1111/j.1472-8206.2009.00684.x

Clinicaltrials, Gov, Prophylaxis Covid-19 In Healthcare Agents By Intensive Treatment With Ivermectin And Iota-Carrageenan

Cottam, Maier, Manifava, Vaux, Chandra-Schoenfelder et al., Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate, Autophagy, doi:10.4161/auto.7.11.16642

De Melo, Lazarini, Larrous, Feige, Kergoat et al., Anti-COVID-19 efficacy of ivermectin in the golden hamster, bioRxiv, doi:10.1101/2020.11.21.392639

Elgazzar, Hany, Youssef, Hafez, Moussa et al., Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic

Hashim, Maulood, Rasheed, Fatak, Kabah et al., Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq

Henry, De Oliveira, Benoit, Plebani, Lippi, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis, Clin Chem Lab Med, doi:10.1515/cclm-2020-0369

Jermain, Hanafin, Cao, Lifschitz, Lanusse et al., Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing, J Pharm Sci, doi:10.1016/j.xphs.2020.08.024

Kirti, Low Low Low Low Low Low Good

Kirti, Roy, Pattadar, Raj, Agarwal et al., Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial, doi:10.1101/2021.01.05.21249310

Kramer, Grandi, Passeri, Gianelli, Genchi et al., Evaluation of lung pathology in Dirofilaria immitis-experimentally infected dogs treated with doxycycline or a combination of doxycycline and ivermectin before administration of melarsomine dihydrochloride, Veterinary parasitology

Krolewiecki, Lifschitz, Moragas, Travacio, Valentini et al., Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial

Liu, Liang, Chen, Wang, Qu et al., Ivermectin induces autophagymediated cell death through the AKT/mTOR signaling pathway in glioma cells, Biosci Rep, doi:10.1042/BSR20192489

Navarro, Camprubí, Requena-Méndez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: a systematic review and meta-analysis, Journal of Antimicrobial Chemotherapy

Niaee, Gheibi, Namdar, Allami, Zolghadr et al., Invermctin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized, multi-center clinical trial

Okumus, Ivermectin for Severe COVID-19 management

Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study, IMC J Med Sci

Raad, In vivo use of ivermectin (IVR) for treatment for corona virus infected patients (COVID-19): a randomized controlled trial

Rezai, Effect of Ivermectin on COVID-19: A multicenter double-blind randomized clinical trial

Schmith, Zhou, Lohmer, The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19, Clinical Pharmacology & Therapeutics

Singh, Mittal, Gollapudi, Butzmann, Kumar et al., A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity, International journal of laboratory hematology

Spoorthi, Utiilty of Ivermectin and Doxycycline combination for the treatment of SARS-CoV-2, IAIM

Stolberg, Lafraniere, Warning of Shortages, Researchers Look to Stretch Vaccine Supply

Tay, Poh, Rénia, Macary, Ng, The trinity of COVID-19: immunity, inflammation and intervention, Nat Rev Immunol, doi:10.1038/s41577-020-0311-8

The, Investigators, Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 -Preliminary report, doi:10.1101/2021.01.07.21249390

Tzou, Tao, Nouhin, Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds, Viruses, doi:10.3390/v12091006

Van Nguyen, Ferrand, Cohen-Boulakia, Martinez, Kapp et al., RCT studies on preventive measures and treatments for COVID-19

Ventre, Rozières, Lenief, Albert, Rossio et al., Topical ivermectin improves allergic skin inflammation, Allergy, doi:10.1111/all.13118

Wang, Gao, Dou, Chen, Li et al., Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer, Autophagy, doi:10.1080/15548627.2016.1231494

Who, WHO Coronavirus Disease (COVID-19) Dashboard

Yan, Ci, Chen, Chen, Li et al., Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, doi:10.1007/s00011-011-0307-8

Zhang, Song, Ci, Ju, Li, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8

Zhang, Song, Xiong, Ci, Li et al., Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol, doi:10.1016/j.intimp.2008.12.016

Zhu, Cong, Yu, Bresnahan, Shenk, Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication, Proc Natl Acad Sci U S A, doi:10.1073/pnas.052713799

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0